November 2019: A link to patient decision aids was added by NICE. Recommendation 1.6.5 was updated to add a crosslink to recommendation 1.6.18 to clarify the topics that should be discussed with a person before making a mammographic surveillance decision. March 2017: NICE has made new recommendations on chemoprevention. The recommendations in this guideline on pages 24, 25 and 189 that are marked with grey shading have been replaced.
Familial Breast Cancer
NICE Clinical Guidelines, No. 164
Authors
National Collaborating Centre for Cancer (UK).This guidance updates and replaces NICE clinical guideline 14 (published May 2004) and NICE clinical guideline 41 (published July 2006).
New and updated recommendations have been included on genetic testing thresholds, surveillance and risk reduction and treatment strategies for people without breast cancer who are at increased risk because of a family history of breast, ovarian or a related cancer. New recommendations have been included on genetic testing thresholds, subsequent surveillance and risk-reduction and treatment strategies for people with a diagnosis of breast cancer and a family history of breast, ovarian or a related cancer.
Recommendations are marked to indicate the year of the last evidence review:
- [2004] if the evidence has not been reviewed since the original guideline.
- [2004, amended 2013] indicates that the evidence has not been updated and reviewed since 2004 but an amendment has been made to the recommendation.
- [2006, amended 2013] indicates that the evidence has not been updated and reviewed since 2006 but an amendment has been made to the recommendation.
- [2013] indicates that the evidence has been reviewed but no changes have been made to the recommendation.
- [new 2013] if the evidence has been reviewed and the recommendation has been updated or added.
Appendix G contains recommendations from the [2004 & 2006] guideline that have been deleted from this [2013] update. Details of any replacement recommendations are also included.